A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by State University of New York - Upstate Medical University
Sponsor:
Collaborator:
CTI BioPharma
Information provided by (Responsible Party):
Seung Shin Hahn, State University of New York - Upstate Medical University
ClinicalTrials.gov Identifier:
NCT00660218
First received: April 11, 2008
Last updated: September 12, 2013
Last verified: September 2013
  Purpose

This study involves two phases. Phase I of this study is designed to find out the maximum dose of paclitaxel poliglumex which can be safely given to subjects when combined with cetuximab and radiotherapy in head and neck cancer. Once the maximum safe dose of paclitaxel poliglumex is found, Phase II of the study will continue to find out whether the addition of paclitaxel poliglumex increases tumor response and survival compared to treatment with cetuximab and radiotherapy alone.

An additional 20 patients have been added, to balance data. These patients must be HPV negative.


Condition Intervention Phase
Carcinoma, Squamous Cell
Drug: paclitaxel poliglumex
Biological: cetuximab
Radiation: radiation therapy (IMRT or 3D-CRT)
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer

Resource links provided by NLM:


Further study details as provided by State University of New York - Upstate Medical University:

Primary Outcome Measures:
  • Phase I: the maximum tolerated dose of paclitaxel poliglumex in combination with radiotherapy and cetuximab for locally advanced head and neck cancer [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Phase II: the rate of locoregional control at one year [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The overall response rate (complete and partial response) [ Time Frame: 1 month following treatment and then every 4 months ] [ Designated as safety issue: No ]
  • The acute and late toxicity profile associated with the study regimen [ Time Frame: 1 month following treatment and then every 4 months ] [ Designated as safety issue: Yes ]
  • The duration of control of locoregional disease [ Time Frame: 1 month following treatment and then every 4 months ] [ Designated as safety issue: No ]
  • Overall survival, disease-free survival, and distant relapse rates [ Time Frame: 1 month following treatment and then every 4 months ] [ Designated as safety issue: No ]
  • Tissue PPX accumulation, level of cathepsin B, and estrogen receptor expression [ Time Frame: At time of locoregional disease progression ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: March 2008
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Radiation therapy, cetuximab, paclitaxel poliglumex
Radiation therapy to 69.96 Gy, 2.12 Gy per day for 33 treatments, starting week 2. Cetuximab loading dose of 400 mg/m² week 1, 250 mg/m² weekly for 7 weeks. Paclitaxel poliglumex starting week 2 40 mg/m².
Drug: paclitaxel poliglumex
Phase I: 40 mg/m2 IV weekly in Cohort 1 (first 3 subjects), escalating in increments of 10 mg/m2 for Cohorts 2 through 5 (3 subjects each) until the maximum tolerated dose (up to 80 mg/m2 IV weekly) is established; Phase II: MTD mg/m2 IV weekly as established in Phase I (24 additional subjects)
Other Names:
  • PPX
  • Xyotax
  • CT-2103
Biological: cetuximab
400 mg/m2 IV loading dose one week prior to starting other study treatments, then 250 mg/m2 IV weekly on same day as paclitaxel poliglumex
Other Names:
  • C225
  • Erbitux
Radiation: radiation therapy (IMRT or 3D-CRT)
radiation therapy to the head and neck, consisting of 33 daily fractions of 2.12 Gy for a total of 69.96 Gy, to begin the same day as paclitaxel poliglumex

Detailed Description:

Patients with locally advanced (stage III and IV) head and neck cancer are often managed by radiotherapy with or without chemotherapy because most of them have unresectable tumor, require too extensive surgery, or are medically unfit to go through radical surgery. However, the treatment results from conventionally fractionated radiotherapy for locally advanced head and neck cancers are poor in terms of local control and survival. Therefore, combinations of radiation and chemotherapy have been studied to improve treatment results.

Sequential radiation-chemotherapy (most given in neo-adjuvant setting) has been studied extensively in prospective pilot and large randomized trials. So far, a survival advantage over standard radiotherapy has not been demonstrated, but organ preservation has been achieved in many patients. Response rates to chemotherapy are high, and decrease in distant metastases has been demonstrated in some trials. Despite a high response rate in trials comparing neoadjuvant chemotherapy and radiotherapy to radiotherapy alone, improved locoregional control (LRC) has not been shown. Concurrent radiation and cisplatin-based chemotherapy has shown survival advantage over radiotherapy alone in meta-analysis. However, the administration of cisplatin-based chemotherapy is associated with significantly increased local and systemic toxic effects, which may preclude many patients from proceeding with combined therapy. Therefore, there is a great interest in defining an active regimen that does not contain cisplatin.

An alternative approach to concurrent chemotherapy and radiotherapy has emerged with the development of molecular targeted agents. A recently reported randomized phase III study demonstrated improved duration of control of locoregional disease and overall survival with the addition of the antibody against the epidermal growth factor receptor, cetuximab, to definitive radiotherapy in patients with squamous cell carcinoma of the head and neck. Importantly, cetuximab administration did not increase radiation-related toxicity.

The most commonly used chemotherapy other than cisplatin chemotherapy for the treatment of advanced head and neck cancer is paclitaxel. There are many studies showing improvement of tumor control when paclitaxel was added to the radiotherapy. Paclitaxel poliglumex (PPX, CT-2103, Xyotax) is a macromolecule that consists of a biodegradable, water-soluble polymer of glutamic acid, a naturally-occurring amino acid, linked to paclitaxel. Preclinical studies suggest increased tumor uptake of PPX compared with paclitaxel, resulting in enhanced tumor cell kill. PPX may potentiate tumor radiocurability without affecting acute normal tissue injury. Moreover, a synergistic increase in tumor cell death was observed when paclitaxel poliglumex was administered with cetuximab in a preclinical tumor model.

The proposed study will assess the rational combination of PPX with radiotherapy and cetuximab. This regimen is of great interest and has the potential to improve the therapeutic ratio compared with an approach of either cisplatin-based chemoradiotherapy or radiotherapy and cetuximab.

There is also an optional tissue submission component of this study, in which subjects who require surgery following their treatment can give permission for a block of tumor tissue removed at the time of their surgery to be sent to Cell Therapeutics, Inc. (the manufacturer of PPX) for evaluation of PPX accumulation, level of cathepsin B, and estrogen receptor expression. This information will be used to correlate the tumor response and survival of patients in the future.

Since the initiation of this study, the relationship of HPV to head and neck cancer has become very evident. Our initial results have many more HPV positive subjects, and therefore we have added 20 more HPV negative patients to the study, to determine if this status affects the outcome.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with histological proof (from the primary lesion and/or cervical lymph node) of squamous carcinoma of the oral cavity, oropharynx, hypopharynx, larynx, or unknown primary.
  • Patients should have stage III or IV disease
  • Patients must have ECOG Performance Status of 0-1
  • Patients must be >/= 18 years of age
  • Patients must have measurable disease
  • Patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count (AGC) of >/= 1500 cells/mm3, platelet count of >/= 100,000 cells/ mm3; adequate hepatic function with bilirubin </= 1.5mg/dl, AST and ALT </= 2x the upper limit of normal; serum creatinine </= 1.5mg/dl, creatinine clearance >/= 50 ml/min and INR 0.8 - 1.2
  • Patients must sign a study specific informed consent form prior to study entry
  • Final 20 subjects must be HPV negative

Exclusion Criteria:

  • Histology other than squamous cell carcinoma
  • Evidence of metastases (below the clavicle or distant) by clinical or radiographic examinations for phase II study subjects
  • History of malignancy other than non-melanoma skin cancer
  • Prior chemotherapy or anticancer biologic therapy for any type of cancer, or prior radiotherapy to the head and neck region except for radioactive iodine therapy
  • Prior history of allergy or hypersensitivity to cetuximab or paclitaxel
  • Weight loss > 10% in the past three months
  • Patients with uncontrolled intercurrent disease
  • Patients with currently active malignancy
  • Pregnant or lactating women
  • Female patients of childbearing potential who are unwilling to practice adequate contraception during study treatment and for two months after the last administration of study drug
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00660218

Contacts
Contact: Dena R Martin, CRA 315-464-5262 martind@upstate.edu

Locations
United States, New York
SUNY Upstate Medical University Recruiting
Syracuse, New York, United States, 13210
Sponsors and Collaborators
State University of New York - Upstate Medical University
CTI BioPharma
Investigators
Principal Investigator: Seung Shin Hahn, MD State University of New York - Upstate Medical University
  More Information

No publications provided

Responsible Party: Seung Shin Hahn, MD, State University of New York - Upstate Medical University
ClinicalTrials.gov Identifier: NCT00660218     History of Changes
Other Study ID Numbers: X90003
Study First Received: April 11, 2008
Last Updated: September 12, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by State University of New York - Upstate Medical University:
Stage III and IV head and neck cancer

Additional relevant MeSH terms:
Head and Neck Neoplasms
Carcinoma, Squamous Cell
Neoplasms by Site
Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Paclitaxel
Cetuximab
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on October 01, 2014